LLY

999.26

-0.72%↓

JNJ

228.04

-0.74%↓

ABBV

209.97

-0.24%↓

UNH

391

-2.31%↓

AZN

181.67

-1.91%↓

LLY

999.26

-0.72%↓

JNJ

228.04

-0.74%↓

ABBV

209.97

-0.24%↓

UNH

391

-2.31%↓

AZN

181.67

-1.91%↓

LLY

999.26

-0.72%↓

JNJ

228.04

-0.74%↓

ABBV

209.97

-0.24%↓

UNH

391

-2.31%↓

AZN

181.67

-1.91%↓

LLY

999.26

-0.72%↓

JNJ

228.04

-0.74%↓

ABBV

209.97

-0.24%↓

UNH

391

-2.31%↓

AZN

181.67

-1.91%↓

LLY

999.26

-0.72%↓

JNJ

228.04

-0.74%↓

ABBV

209.97

-0.24%↓

UNH

391

-2.31%↓

AZN

181.67

-1.91%↓

Strona główna・Stock List・Roivant Sciences Ltd

Roivant Sciences Ltd

Open

SectorHealthcare

28.76 -1.88

Buy Sell

Overview

Share price change

24h

Current

Min

28.75

Max

29.64

Key metrics
By Trading Economics
Income	-200M -314M
Sales	428K 2M
Profit margin	-15,692.896
Employees	750
EBITDA	-132M -290M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+20.84% upside

Market Stats
By TradingEconomics
Market Cap	5.5B 21B
Previous open	30.64
Previous close	28.76

News Sentiment

By Acuity

67%

33%

307 / 346 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

11 / 11.18 Support & Resistance

Roivant Sciences Ltd Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 maj 2026, 22:44 UTC

Acquisitions, Mergers, Takeovers

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14 maj 2026, 22:27 UTC

Acquisitions, Mergers, Takeovers

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14 maj 2026, 22:12 UTC

Earnings

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14 maj 2026, 21:52 UTC

Acquisitions, Mergers, Takeovers

LVMH to Sell Marc Jacobs

15 maj 2026, 00:00 UTC

Earnings

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14 maj 2026, 23:57 UTC

Acquisitions, Mergers, Takeovers

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14 maj 2026, 23:56 UTC

Acquisitions, Mergers, Takeovers

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14 maj 2026, 23:56 UTC

Acquisitions, Mergers, Takeovers

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14 maj 2026, 23:56 UTC

Market Talk

Gold Prices Rise on Strong Demand -- Market Talk

14 maj 2026, 23:56 UTC

Acquisitions, Mergers, Takeovers

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14 maj 2026, 23:50 UTC

Market Talk

Global Equities Roundup: Market Talk

14 maj 2026, 23:50 UTC

Market Talk

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14 maj 2026, 23:47 UTC

Earnings

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14 maj 2026, 23:47 UTC

Earnings

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14 maj 2026, 23:46 UTC

Earnings

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14 maj 2026, 23:46 UTC

Earnings

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14 maj 2026, 23:28 UTC

Market Talk

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14 maj 2026, 23:00 UTC

Market Talk

Australia's One Nation Party Leads In The Polls -- Market Talk

14 maj 2026, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

14 maj 2026, 22:46 UTC

Market Talk

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14 maj 2026, 22:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 maj 2026, 22:35 UTC

Market Talk

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14 maj 2026, 22:11 UTC

Acquisitions, Mergers, Takeovers

LVMH Agrees to Sell Marc Jacobs -- WSJ

14 maj 2026, 22:06 UTC

Market Talk

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14 maj 2026, 22:04 UTC

Earnings

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14 maj 2026, 22:04 UTC

Earnings

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14 maj 2026, 22:04 UTC

Earnings

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14 maj 2026, 22:00 UTC

Earnings

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14 maj 2026, 21:55 UTC

Earnings

Nu Holdings 1Q EPS 18c >NU

14 maj 2026, 21:55 UTC

Earnings

Nu Holdings 1Q Rev $4.97B >NU

Peer Comparison

Price change

Roivant Sciences Ltd Forecast

Price Target

By TipRanks

20.84% upside

12 Months Forecast

Average 35.31 USD 20.84%

High 41 USD

Low 29.5 USD

Based on 8 Wall Street analysts offering 12 month price targets forRoivant Sciences Ltd - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Roivant Sciences Ltd - Dist in the past 3 months.

Technical Score

By Trading Central

11 / 11.18Support & Resistance

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentiment

By Acuity

307 / 346 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.